Access & Impact

Viatris Publishes 2024 Sustainability Report: Building Sustainable Access at Scale

Discover Viatris

Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook

Discover Viatris

Viatris Announces Positive Results from Phase 3 Study of Investigational XULANE LO™ Low Dose Patch for Birth Control in Women of Childbearing Potential

Discover Viatris

Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain